[Molecular targeted therapy for neuroimmunological diseases]

Area of Science:

• Neuroimmunology
• Molecular Biology
• Pharmacology

Context:

• Monoclonal antibodies represent a significant advancement in treating neuroimmunological disorders.
• Approved therapies like natalizumab for multiple sclerosis and off-label rituximab for neuromyelitis optica highlight current clinical applications.
• These biological compounds offer targeted action against pathogenic cells, minimizing off-target effects.

Purpose:

• To review the efficacy and application of monoclonal antibodies in neuroimmunological diseases.
• To discuss the specificity and potential side effects of these targeted therapies.
• To address the economic considerations of continuous monoclonal antibody treatment.

Summary:

• Monoclonal antibodies are highly specific biological agents demonstrating efficacy in treating multiple sclerosis, neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and polymyositis.
• Natalizumab was the first approved monoclonal antibody for multiple sclerosis treatment (outside Japan), while rituximab is used for neuromyelitis optica despite lacking FDA approval.
• Their targeted nature promises high specificity and reduced side effects, though cost-effectiveness for long-term use is a consideration.

Impact:

• Monoclonal antibody therapy has transformed the management of several debilitating neuroimmunological conditions.
• The development of targeted therapies offers hope for more effective and safer treatment options.
• Future research may focus on optimizing treatment protocols and addressing the cost barriers associated with these advanced therapies.